

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IFW

In re Applicant:

Eduardo N. MITRANI

Serial No.: 10/009,520

Filed: May 3, 2002

For: METHOD OF INDUCING ANGIOGENESIS
BY MICRO-ORGANS

Examiner: ANGELL, JON E

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



§
§
§
§
§
§
§
§
§
§
§

Group Art Unit: 1635

Attorney
Docket: 01/22858

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Supplemental Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Martin D. Moynihan
Registration No. 40,338

Dated: July 3, 2006

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/009,520
				Filing Date	May 3, 2002
				First Named Inventor	Eduardo N. MITRANI
				Group Art Unit	1635
				Examiner Name	ANGELL, JON E
Sheet	2	of	3	Attorney Docket Number	01/22858
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	14	Soyer et al. "Extracorporeal Assist of Anhepatic Animals With Liver Slice Perfusion", The American Journal of Surgery, P.21-26, 1973.			
	15	Rubanyi "The Future of Human Gene Therapy", Molecular Aspects of Medicine, 22(3): 113-142, 2001.			
	16	Parrish et al. "Minireview : Precision-Cut Tissue Slices: Applications in Pharmacology and Toxicology", Life Sciences, 57(21): 1887-1901, 1995.			
	17	Villevall et al. "Retrovirus-Mediated Transfer of the Erythropoietin Gene in Hematopoietic Cells Improves the Erythrocyte Phenotype in Murine β -Thalassemia", Blood, 84(3): 928-933, 1994.			
	18	Descamps et al. "Organoids Direct Systematic Expression of Erythropoietin in Mice", Gene Therapy, 2: 411-417, 1995.			
	19	Palù et al. "In Pursuit of New Developments for Gene Therapy of Human Diseases", J. Biotechnology, 68: 1-13, 1999.			
	20	Romano et al. "Gene Transfer Technology in Therapy: Current Applications and Future Goals", Stem Cell, 17: 191-202, 1999.			
	21	Kappel et al. "Regulating Gene Expression in Transgenic Animals", Current Opinion in Biology, 3: 548-553, 1992.			
	22	Mullins et al. "Transgenesis in Nonmurine Species", Hypertension, 22(4): 630-633, 1993.			
	23	Mullins et al. "Transgenesis in the Rat and Larger Mammals", J. Clin. Invest., 97(7): 1557-1560, 1996.			
	24	Houdebine "Production of Pharmaceutical Proteins From Transgenic Animals", J. Biotechnology, 34: 269-287, 1994.			
	25	Wall "Transgenic Livestock: Progress and Prospects for the Future", Transgenology, 45: 57-68, 1996.			
	26	Sigmund "Viewpoint: Are Studies in Genetically Altered Mice Out of Control?", Arterioscler. Thromb. Vasc. Biol., 20: 1425-1429, 2000.			
	27	Niemann "Transgenic Farm Animals Get Off the Ground", Transgenic Research, 7: 73-75, 1998.			
	28	Crystal "Transfer of Genes to Humans: Early Lessons and Obstacles to Success", Science, 270: 404-410, 1995.			
	29	Verma et al. "Gene Therapy - Promises, Problems and Prospects", Nature, 389: 239-242, 1997.			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/009,520
				Filing Date	May 3, 2002
				First Named Inventor	Eduardo N. MITRANI
				Group Art Unit	1635
				Examiner Name	ANGELL, JON E
Sheet	3	of	3	Attorney Docket Number	01/22858
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	30	Deonarain "Ligand-Targeted Receptor-Mediated Vectors for Gene Delivery", Exp. Opin. Ther. Patents, 8(1): 53-69, 1998.			
	31	Miller et al. "Targeted Vectors for Gene Therapy", FASEB J., 9: 190-199, 1995.			
	32	Eck et al. "Gene-Based Therapy", in: Goodman & Gilman's 'The Pharmacological Basis of Therapeutics', 9/E, Chap.5: 77-101, 1997.			
	33	Ledley "Pharmaceutical Approach to Somatic Gene Therapy", Pharm. Res., 13(11): 1595-1614, 1996.			
	34	Saadi et al. "Immunology of Xenotransplantation", Life Sciences, 62(5): 365-387, 1998.			
	35	Inverardi et al. "Cell Transplantation", in: 'Transplantation Biology: Cellular and Molecular Aspects', Raven Pub., Chap. 56, 1996.			
	36	Philpott et al. "Rat Hair Follicle Growth In Vivo", Br. J. Derm., 127: 600-607, 1992.			
	37	Lingna "Skin Toxicity Determined In Vitro by Three-Dimensional, Native-State Histoculture", Proc. Natl. Acad. Sci. USA, 88: 1908-1912, 1991.			
	38	Cameron "Recent Advances in Transgenic Technology", Molecular Biotechnology, 7: 253-265, 1997.			
	39	Eto et al. "Purification and Characterization of Erythroid Differentiation Factor (EDF) Isolated From Human Leukemia Cell Line THP-1", Biochemical and Biophysical Research Communications, 142(3): 1095-1103, 1987.			
	40	Chesnokova et al. "The Thymic Factor Tactivin Prevents ACTH From Stimulating Steroidogenesis by Mouse Adrenal Cells", Institute of Cytology and Genetics, USSR Academy of Science, 1990.			
Signature				Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.